Acquired by GeneBlue in 2007, Unitech Pharmaceuticals had been engaged in the discovery and development of novel treatments for a variety of autoimmune diseases and cancer. The firm had focused on developing treatments for rheumatoid arthritis, cancer, psoriasis and other conditions. While financial terms of the deal were not disclosed, the sale included nearly all of Unitech's patents and related technology.
